Collaboration and Research Arrangements |
9 Months Ended |
---|---|
Sep. 30, 2024 | |
Collaborative Arrangement Disclosure [Abstract] | |
Collaboration and Research Arrangements | 3. Collaboration and Research Arrangements During the three and nine months ended September 30, 2023, the Company recognized revenue of $3.8 million and $9.6 million, respectively, under a license and collaboration agreement with Global Therapeutics, Inc, now a subsidiary of Pfizer. As the agreement was terminated in October 2023, no revenue was recognized during the three and nine month periods ended September 30, 2024. |